Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma.

Laucis, Anna M; Selwa, Katherine; Sun, Yilun; Kim, Michelle M; Cuneo, Kyle C; Lawrence, Theodore S; Wahl, Daniel R; Junck, Larry; Umemura, Yoshie

Laucis, Anna M; Selwa, Katherine; Sun, Yilun; Kim, Michelle M; Cuneo, Kyle C; Lawrence, Theodore S; Wahl, Daniel R; Junck, Larry; Umemura, Yoshie.

Afiliação

Laucis AM; Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Selwa K; Department of Neurology, University of Michigan Hospital, Ann Arbor, MI, USA.
Sun Y; Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Kim MM; Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Cuneo KC; Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Lawrence TS; Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Wahl DR; Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Junck L; Department of Neurology, University of Michigan Hospital, Ann Arbor, MI, USA.
Umemura Y; Department of Neurology, University of Michigan Hospital, Ann Arbor, MI, USA.

Neurooncol Pract ; 9(6): 536-544, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36388411

Palavras-chave

central nervous system; lymphoma; temozolomide; whole brain radiotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google